Filing Flows › AIM ImmunoTech (AIM) › Q1 2025
AIM ImmunoTech (AIM) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
AIM ImmunoTech (AIM) reported revenue of $16K for the first quarter 2025 (Q1 2025), -60% from a year earlier and -64% from the quarter before.
AIM ImmunoTech, Q1 2025: revenue $16K (-60% year over year), net loss $3.7M, operating cash flow −$2.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $16K | -64% | -60% |
| Operating profit | −$3.6M | — | — |
| Net earnings | −$3.7M | — | — |
| Operating cash flow | −$2.4M | — | — |
What changed
Revenue was $16K in Q1 2025, down 60% year over year and down 64% from the previous quarter.
Operating costs exceeded revenue by $3.6M, an operating margin of -22618.8%. Total costs fell 37% while revenue fell 60%. The quarter ended with a net loss of $3.7M, narrower than the previous quarter's $6.0M loss.
Operating cash flow was −$2.4M. Non-cash charges added back $58K of depreciation and amortization and $60K of share-based compensation. Working capital and other items added $1.2M.
Questions
What was AIM ImmunoTech's revenue in the first quarter 2025?
AIM ImmunoTech (AIM) reported revenue of $16K for the first quarter 2025 (Q1 2025), -60% from a year earlier and -64% from the quarter before.
Source: AIM ImmunoTech 10-Q on SEC EDGAR.